Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07875933
PHASE3

Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects

Sponsor: Onconic Therapeutics Inc.

View on ClinicalTrials.gov

Summary

This study aims to evaluate the Efficacy and Safety of JP-1366-based Triple-Therapy in H. pylori-positive Subjects

Official title: A Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Non-inferiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects

Key Details

Gender

All

Age Range

19 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

414

Start Date

2026-11-01

Completion Date

2028-10-06

Last Updated

2026-10-15

Healthy Volunteers

No

Interventions

DRUG

JP-1366 20 mg, Lansoprazole 30 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg

Orally, twice daily

DRUG

Lansoprazole 30mg, JP-1366 20 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg

Orally, twice daily